Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 17/20 | 0.42 |
| ▸ | PRKDC | P78527 | 3/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 12/20 | 0.37 |
| ▸ | MTOR | P42345 | 12/20 | 0.37 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.36 |
| ▸ | ATR | Q13535 | 5/20 | 0.36 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.36 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.36 |
| ▸ | ATRIP | Q8WXE1 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23119283 | 1.00 | ATM (0.42) | ATMPRKDCPIK3CAMTORHRH4 | |
| SCHEMBL29688033 | 0.90 | ATM (0.42) | ATMPRKDCPIK3CAMTORATR | |
| SCHEMBL23119289 | 0.90 | ATM (0.42) | ATMPRKDCPIK3CAMTORATR | |
| SCHEMBL23119298 | 0.89 | ATM (0.54) | ATMPRKDCPIK3CAMTORATR | |
| SCHEMBL23093830 | 0.89 | ATM (0.54) | ATMPRKDCPIK3CAMTORATR | |
| SCHEMBL23119299 | 0.89 | ATM (0.54) | ATMPRKDCPIK3CAMTORATR | |
| SCHEMBL29742730 | 0.88 | CTSS (0.41) | ATMPRKDCPIK3CAMTORATR | |
| SCHEMBL21541780 | 0.86 | ATM (0.51) | ATMPRKDCPIK3CAMTORHRH4 | |
| SCHEMBL23119186 | 0.84 | ATM (0.49) | ATMPRKDCPIK3CAMTORATR | |
| SCHEMBL30192387 | 0.82 | ATM (0.39) | ATMPRKDCPIK3CAMTORATR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220354859-A1 | SUBSTITUTED IMIDAZOQUINOXALINE COMPOUNDS AND USES THEREOF | Impact Therapeutics (Shanghai), Inc (CN) | 2022-11-10 | — | — | US | claimed |
| EP-4028400-A1 | SUBSTITUTED IMIDAZOQUINOXALINE COMPOUNDS AND USES THEREOF | Impact Therapeutics (Shanghai), Inc (CN) | 2022-07-20 | — | — | EP | claimed |
| US-20220354859-A1 | SUBSTITUTED IMIDAZOQUINOXALINE COMPOUNDS AND USES THEREOF | Impact Therapeutics (Shanghai), Inc (CN) | 2022-11-10 | — | — | US | disclosed |
| EP-4028400-A1 | SUBSTITUTED IMIDAZOQUINOXALINE COMPOUNDS AND USES THEREOF | Impact Therapeutics (Shanghai), Inc (CN) | 2022-07-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220354859-A1 | SUBSTITUTED IMIDAZOQUINOXALINE COMPOUNDS AND USES THEREOF | CHEK2, CHEK1, ATM | ATM 3/4885PRKDC 26/4885PIK3CA 164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.